Ramucirumab: first global approval. - Wikidata - awgldk - TriplyDB

Ramucirumab: first global approval.

Ramucirumab: first global approval.

http://www.wikidata.org/entity/Q38219239

about

Current Molecular Targeted Therapy in Advanced Gastric Cancer: A Comprehensive Review of Therapeutic Mechanism, Clinical Trials, and Practical Application Novel targeted agents for the treatment of lung cancer in China Ramucirumab: preclinical research and clinical development.Anti-angiogenic therapies for advanced esophago-gastric cancer At least two Fc Neu5Gc residues of monoclonal antibodies are required for binding to anti-Neu5Gc antibody DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo.Incidence and relative risk of hemorrhagic events associated with ramucirumab in cancer patients: a systematic review and meta-analysis.Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives.The coming of ramucirumab in the landscape of anti-angiogenic drugs: potential clinical and translational perspectives.Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment.Development of antibody-based c-Met inhibitors for targeted cancer therapy.A Review of Anti-Angiogenic Targets for Monoclonal Antibody Cancer Therapy Chemotherapy for Hepatocellular Carcinoma: Current Evidence and Future Perspectives Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer.Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials

P2860

Q26765941-4FDB0AA9-B57A-4D14-AC97-155B75C6F82F Q26786580-AF4DE92D-8926-4660-9463-4196043C9568 Q34446310-5ECFF676-876D-4B40-B916-0BF229BF9964 Q34686222-A88B6B47-C2EF-435F-9C13-63E635F455B7 Q36517187-912055A4-F3E3-4A40-B79F-177B0190DBC2 Q36644256-FD28A347-4974-464F-9064-5CF0581FC4BE Q37662388-6DDBC9DE-3174-47A4-ADE3-F180BB419A8B Q38473672-B6F2C141-3ED0-43A9-84A9-C8CE383329E7 Q38550459-E56D5DDD-FFC7-42B5-A97F-4B843984CCC2 Q38852051-9D1CADD3-0D7E-459B-8BD0-E6B471C80C65 Q38912279-8AAEAC52-0ACE-4BD2-BCFD-932990864196 Q41574359-1CE40140-B11E-48E2-B116-E4649B4610E1 Q41706847-F59D0666-D4CA-4B56-84CE-FD4227E07541 Q44645655-3D14D927-132C-4FA7-B7E9-A2A6EA372CB4 Q58729601-1C627D1C-3347-44EA-9589-166ACB00CB0A

P2860

Ramucirumab: first global approval.

http://www.wikidata.org/entity/Q38219239

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年学术文章

@wuu

2014年学术文章

@zh-cn

2014年学术文章

@zh-hans

2014年学术文章

@zh-my

2014年学术文章

@zh-sg

2014年學術文章

@yue

2014年學術文章

@zh

2014年學術文章

@zh-hant

name

Ramucirumab: first global approval.

@en

type

label

Ramucirumab: first global approval.

@en

prefLabel

Ramucirumab: first global approval.

@en

P1433

Q38219239-F16F98D1-583B-4295-A506-88CCF8F84C23

P1476

Q38219239-1376A13B-24E1-4DE0-81FA-983B004EC266

P2093

Q38219239-CC2F6A20-F588-48BD-8265-B83E726BF367

Q38219239-E66E7533-E4F9-47FE-B7F7-3C9C06FE4D4C

P2860

Q38219239-071899F4-F163-45A8-9131-69A8F359A941

Q38219239-17A282EE-9649-4FC1-A947-DAE53653ADA4

Q38219239-459BB080-BD85-4E93-95A8-4451309CF310

Q38219239-4A237E50-3CBA-4A49-B502-E98DB3DE24D6

Q38219239-78705D5D-360C-4F6D-953F-D6117777802C

Q38219239-9B60B5CE-B793-41EB-913A-E34FF2180899

Q38219239-9C81342B-6774-4662-AEB7-3C7DAB659E60

Q38219239-ADB907C2-3768-4E66-BC7E-722B27DB1C40

Q38219239-E199F6CD-4ADE-4352-8A69-A932210C848C

Q38219239-E65E4BA0-D7E3-42F0-9A6A-60E27F210E86

P2888

Q38219239-7F4A8B45-36A4-49BE-BFFF-ECBCFDF60DC1

P304

Q38219239-D9804AF7-972C-44CE-A3A6-BF51590C9CC2

P31

Q38219239-9EF65D77-15B3-46F1-AC4F-CB7F9D46E8A1

P356

Q38219239-549CFA9D-06A5-4DEF-B6EC-CC4BC03F7F44

P433

Q38219239-3F1697D9-3DCA-4C9F-9580-15B1A9C9BB13

P478

Q38219239-73D2A79D-D196-4C57-B776-9C221BD0D3F5

P577

Q38219239-822690C2-CFAA-4E94-A358-C5520E91ACC1

P6179

Q38219239-438169BE-75F4-4381-B078-3F3813122ACC

P698

Q38219239-CC4B4ABA-3CB7-4D82-9F34-59E070C4F886

P356

S40265-014-0244-2

P1433

P1476

Ramucirumab: first global approval.

@en

P2093

Asha Vaidya

http://www.w3.org/2001/XMLSchema#string

Raewyn M Poole

http://www.w3.org/2001/XMLSchema#string

P2860

The structural basis for the function of two anti-VEGF receptor 2 antibodies

Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial

Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2.

Targeted inhibition of VEGF receptor 2: an update on ramucirumab.

Targeted systemic therapies for hepatocellular carcinoma: clinical perspectives, challenges and implications

A phase II and biomarker study of ramucirumab, a human monoclonal antibody targeting the VEGF receptor-2, as first-line monotherapy in patients with advanced hepatocellular cancer.

The progress of targeted therapy in advanced gastric cancer

Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.

VEGFA and tumour angiogenesis.

Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.

P2888

s40265-014-0244-2

P304

1047-1058

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S40265-014-0244-2

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P577

2014-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1035014957

http://www.w3.org/2001/XMLSchema#string

P698

24916147

http://www.w3.org/2001/XMLSchema#string